# AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

- Link: https://www.directorstalkinterviews.com/astrazeneca-reports-strong-growth-and-pipeline-momentum-in-fy-and-q4-2023/4121141811
- Published: 2024-02-08T07:27:00+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced its FY and Q4 2023 results.

Strong growth and pipeline momentum with three new medicines approved since the 
third quarter

**Revenue and EPS summary**

|  |  |  | FY 2023 |  |  | Q4 2023 |  | 
|  |  |  | % Change |  | % Change | 
| ** ** | ** ** | **$m**  | **Actual**  | **CER^([1])** | **$m**  | **Actual**  | **CER**  | 
| – Product Sales |  | 43,789  | 2  | 4  | 11,323  | 5  | 5  | 
| – Alliance Revenue^([2]) |  | 1,428  | 89  | 89  | 424  | 69  | 67  | 
| – Collaboration Revenue^(2) |  | 594  | (1) | (1) | 277  | 75  | 74  | 
| Total Revenue |  | 45,811  | 3  | 6  | 12,024  | 7  | 8  | 
| _Total Revenue ex COVID-19_ | _ _ | _45,488 _ | _13 _ | _15 _ | _12,036 _ | _16 _ | _16 _ | 
| Reported EPS |  | $3.84_ _ | 81  | 96  | $0.62_ _ | 7  | 5  | 
| Core^([3]) EPS |  | $7.26_ _ | 9  | 15  | $1.45_ _ | 5  | 7  |

**Financial performance for full year 2023 (Growth numbers at CER)**

‒    Total Revenue $45,811m, up 6% despite a decline of $3,736m from COVID-19 medicines
^([4])

‒    Excluding COVID-19 medicines, Total Revenue increased 15% and Product Sales
increased 14%

‒    Double-digit Total Revenue growth from Oncology 21%, CVRM 18%, R&I 10%, and
Rare Disease 12%

‒    Core Product Sales Gross Margin^([5]) of 82%, up two percentage points, reflecting
the decline in sales of lower margin COVID‑19 medicines

‒    Core Operating Margin of 32% increased by two percentage points including the
previously announced gain from an update to the contractual relationships for _Beyfortus_,
totalling $712m and recorded as Core Other operating income. In the quarter, higher
SG&A expense drove lower operating margins, partly due to phasing of expenses and
increased investment in launches for _Airsupra, Wainua_ and _Truqap_

‒    The Core Tax Rate for the year was 17%. In the fourth quarter, the tax rate
was negatively impacted by reviews by tax authorities, administrative appeal processes
and other adjustments, offset by a routine intragroup reorganisation of IP, leading
to a tax rate of 10% in the quarter

‒    Core EPS increased 15% to $7.26

‒    Second interim dividend declared of $1.97 per share, making a total dividend
declared for FY 2023 of $2.90 per share

‒    Total Revenue and Core EPS in FY 2024 are each expected to increase by a low
double-digit to low teens percentage at CER

> **Pascal Soriot, Chief Executive Officer, said:**
> “As AstraZeneca celebrates its 25th anniversary, we are pleased to report another
> year of strong financial performance and scientific progress, with double-digit
> earnings growth, and investment in exciting areas of science, including antibody
> drug conjugates and cell therapies, that lay the foundations for long-term success.
> We expect another year of strong growth in 2024, driven by continued adoption 
> of our medicines across geographies. Our differentiated and growing portfolio 
> of approved medicines, global reach and rich R&D pipeline give us confidence that
> we will continue to deliver industry-leading growth.”

**Key milestones achieved since the prior results announcement**

‒    Three first approvals for new molecular entities: _Truqap_ (capivasertib), 
_Wainua_ (eplontersen), _Voydeya_ (danicopan)

‒    US approvals for _Truqap_ plus _Faslodex_ in HR-positive, HER2-negative advanced
breast cancer with biomarker alterations (CAPItello‑291), and _Wainua_ for ATTRv-
PN (NEURO-TTRansform). China approvals for _Imfinzi_ in mBTC (TOPAZ-1) and _Beyfortus_
for prevention of RSV in infants (MEDLEY/MELODY). First approval, in Japan, for 
_Voydeya_, as an add-on therapy to _Ultomiris_ or _Soliris_ for PNH with EVH (ALPHA)

‒    _Enhertu_ granted Priority Review in the US for patients with metastatic HER2-
positive solid tumours

**Guidance**

The Company issues its Total Revenue and Core EPS guidance for FY 2024 at CER, based
on the average foreign exchange rates through 2023.

Total Revenue is expected to increase by a low double-digit to low teens percentage

Core EPS is expected to increase by a low double-digit to low teens percentage

‒    Collaboration Revenue is expected to increase substantially, driven by success-
based milestones and certain anticipated transactions

‒    Other operating income is expected to decrease substantially (FY 2023 included
a $241m gain on the disposal of _Pulmicort Flexhaler_ US rights, and a $712m one-
time gain relating to updates to contractual arrangements for _Beyfortus_)

‒    The Core Tax rate is expected to be between 18-22%

The Company is unable to provide guidance on a Reported basis because it cannot 
reliably forecast material elements of the Reported results, including any fair 
value adjustments arising on acquisition-related liabilities, intangible asset impairment
charges and legal settlement provisions. Please refer to the cautionary statements
section regarding forward-looking statements at the end of this announcement.

**Currency impact**

If foreign exchange rates for February 2024 to December 2024 were to remain at the
average rates seen in January 2024, it is anticipated that both FY 2024 Total Revenue
and Core EPS would incur a low single-digit adverse impact versus the performance
at CER. The Company’s foreign exchange rate sensitivity analysis is provided in 
Table 19.

**Investor Day**

AstraZeneca will host an Investor Day on 21 May 2024. For more information, see 
www.astrazeneca.com/investor-relations.html .

**Corporate and business development**

In November 2023, AstraZeneca launched Evinova, with an ambition to become a leading
provider of digital health solutions to better meet the needs of healthcare professionals,
regulators and patients. Evinova will prioritise bringing to market established 
and scaled digital technology solutions already being used globally by AstraZeneca
to optimise clinical trial design and delivery. Globally-leading clinical research
organisations Parexel and Fortrea have entered into agreements to offer Evinova 
digital health solutions to their wide customer base.

In December 2023, AstraZeneca entered into a definitive agreement to acquire Icosavax,
Inc (Icosavax). The acquisition strengthens AstraZeneca’s late-stage pipeline with
Icosavax’s lead investigational vaccine candidate, IVX-A12, a potential first-in-
class, Phase III-ready, combination VLP vaccine that targets both RSV and hMPV. 
RSV and hMPV are both leading causes of severe respiratory infection and hospitalisation
in adults 60 years of age and older and those with chronic conditions such as cardiovascular,
renal and respiratory disease. Subject to the satisfaction of the conditions in 
the merger agreement, the acquisition is expected to close in the first quarter 
of 2024.

In December 2023, AstraZeneca entered into a definitive agreement to acquire Gracell
Biotechnologies Inc. (Gracell), a global clinical-stage biopharmaceutical company
developing innovative cell therapies for the treatment of cancer and autoimmune 
diseases. The proposed acquisition will enrich AstraZeneca’s growing pipeline of
cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19
dual-targeting CAR-T therapy, a potential new treatment for multiple myeloma, as
well as other haematologic malignancies and autoimmune diseases including systemic
lupus erythematosus. The transaction is expected to close in the first quarter of
2024, subject to customary closing conditions, including regulatory clearances, 
and Gracell shareholder approval.

In February 2024, AstraZeneca announced that it is investing $300 million in a state-
of-the-art facility in Rockville, Maryland to establish life-saving cell therapy
platforms for critical cancer trials and future commercial supply. To align with
clinical trial timelines, the site will initially focus on pivotal clinical trial
manufacturing of CAR-T cell therapies to meet current clinical supply demand. More
than 150 new highly skilled jobs will be created to initially focus on manufacturing
T-cell therapies to enable clinical trials to be conducted around the world. Over
time, the site may expand its focus to support other therapy areas.

**[Sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
highlights**

Through the Sustainable Markets Initiative Health Systems Task Force, AstraZeneca
announced an industry-first renewable power agreement in China together with four
global healthcare leaders and renewable energy company Envision Energy, resulting
in potential annual emissions savings of approximately 120,000 tonnes, the equivalent
of taking 25,000 cars off the road. See the Sustainability section in this document
for further details.

**Conference call**

A conference call and webcast for investors and analysts will begin today, 8 February
2024, at 11:45 UK time. Details can be accessed via astrazeneca.com.

**Reporting calendar**

The Company intends to publish its Q1 2024 results on 25 April 2024.

[1] Constant exchange rates. The differences between Actual Change and CER Change
are due to foreign exchange movements between periods in 2023 vs. 2022. CER financial
measures are not accounted for according to generally accepted accounting principles(
GAAP) because they remove the effects of currency movements from Reported results.

[2] Effective 1 January 2023, the Group has updated the presentation of Total Revenue.
For further details of the presentation of Alliance Revenue and Collaboration Revenue,
see the Basis of preparation and accounting policies section of the Notes to the
Condensed consolidated financial statements section.

[3] Core financial measures are adjusted to exclude certain items. The differences
between Reported and Core measures are primarily due to costs relating to the acquisition
of Alexion, amortisation of intangibles, impairments, legal settlements and restructuring
charges. A full reconciliation between Reported EPS and Core EPS is provided in 
Table 13 and Table 14 in the Financial performance section of this document.

[4] The COVID-19 medicines are Vaxzevria, Evusheld, and sipavibart (AZD3152) – the
COVID-19 antibody currently in development.

[5] The calculation of Reported and Core Product Sales Gross Margin (formerly termed
as Gross Margin) excludes the impact of Alliance Revenue and Collaboration Revenue.

Share on:
